However, it has been recognised that acquisition of drug resistance by cancer cells also makes them more sensitive to alternative drugs, a phenomenon referred to as ‘collateral sensitivity’.103 Potentially, this sequential or alternating approach could be used for EGFR-mutant NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.